HCPCS Level II code J0179 denotes the administration of brolucizumab-dbll, 1 mg, delivered as an intravitreal injectable biologic therapy used in retinal disease management. This code captures a high-cost specialty ophthalmology drug administered in outpatient clinical settings and is relevant to payers managing utilization and coverage of novel ophthalmic biologics.

Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find national-level context on the code’s clinical role, commonly reported payer coverage types, and practical billing considerations. The publication outlines benchmarks for utilization and units billed where available, summarizes policy and coverage considerations that affect reimbursement workflows, and provides clinical context about the service model (intravitreal injection in outpatient ophthalmology settings).

This summary is intended for stakeholders across billing, clinical operations, and policy teams seeking a concise reference on HCPCS Level II code J0179 — what the code represents, typical sites of service, and the types of analyses and benchmarks included in the full publication. Data not available in the input will be noted where applicable.